BCD-131 versus Mircera for treating anemia in people with end-stage kidney disease on dialysis

A Randomized, Open-label, Comparative Clinical Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

This study will test whether BCD-131 works as well and is as safe as Mircera for treating anemia in adults with end-stage chronic kidney disease who are on regular dialysis.

Quick facts

• Phase: PHASE3
• Study type: Interventional
• Enrollment: 228 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Biocad (industry)
• Locations: 2 sites (Minsk and 1 other locations)
• Trial ID: NCT07119372 on ClinicalTrials.gov

What this trial studies

This is a randomized, open-label Phase 3 trial comparing pegylated darbepoetin beta (BCD-131) with methoxypolyethylene glycol-epoetin beta (Mircera) as maintenance therapy for anemia in patients with stage 5 chronic kidney disease on dialysis. Eligible participants are adults who have been on stable erythropoiesis-stimulating agent (ESA) therapy with target hemoglobin 100–120 g/L and on dialysis for at least 90 days. The main efficacy analysis compares hemoglobin control after a 32-week main period (including dose titration and maintenance), with an extension to week 52 for longer-term safety and efficacy and a short follow-up. The trial is designed as a non-inferiority comparison to see if BCD-131 provides similar hemoglobin maintenance and safety compared with Mircera.

Who should consider this trial

Good fit: Adults aged 18–75 with end-stage kidney disease on hemodialysis for at least 90 days who have been on a stable ESA dose with hemoglobin 100–120 g/L for at least two weeks are ideal candidates.

Not a fit: People not on regular dialysis, those with other causes of anemia (iron, B12/folate deficiency, chronic disease), those with unstable ESA dosing or hemoglobin outside 100–120 g/L, or those outside the 18–75 age range are unlikely to benefit from participating.

Why it matters

Potential benefit: If successful, BCD-131 could provide an additional maintenance treatment option to keep hemoglobin stable in dialysis patients, potentially improving access or offering alternative dosing or cost advantages.

How similar studies have performed: Previous trials of long-acting pegylated erythropoietin agents, including darbepoetin formulations and Mircera, have demonstrated effective hemoglobin maintenance in dialysis patients, so this comparison follows established precedents.

Eligibility criteria

Inclusion Criteria:

* The patient signed a written ICF for participation in the study.
* Men and women aged 18 to 75 years inclusive at the time of signing the ICF.
* End stage kidney disease (documented).
* The need for dialysis sessions within at least the last 90 days prior to signing the ICF.
* For patients on hemodialysis - hemodialysis procedures should be at least 3 times a week, for a total duration of at least 12 hours a week.
* Documented use of recombinant erythropoietin (epoetin alfa, epoetin beta or darbepoetin alfa) for at least 90 days prior to signing the ICF.
* The dose of recombinant erythropoietins (epoetin alfa or epoetin beta received 1, 2 or 3 times a week, or darbepoetin alfa received once a week/once every 2 weeks) should be stable for at least 90 days prior to signing the ICF and the entire screening period (documented).
* Target hemoglobin level (100-120 g/L inclusive) based on the results of screening examination (two measurements).
* The efficacy of dialysis established at screening or not more than 14 days before signing the ICF (dialysis dose index (Kt/v) ≥1.2 in patients on long-term hemodialysis, and weekly Kt/v ≥1.7 for patients on peritoneal dialysis).
* Transferrin saturation ≥20%, ferritin level \>100 ng/mL at screening.
* Cyancobalamine (vitamin B12) and folic acid levels within the laboratory reference values at screening.
* Willingness of patients of both sexes and their sexual partners of childbearing potential to use methods of contraception in accordance with the protocol, starting from signing the informed consent form, throughout the study and for up to 90 days after receiving the last dose of the drug in the clinical study, as well as to refrain from donation of eggs for female subjects or sperm for male subjects during this period.
* The ability of the patient to comply with the Protocol requirements, in the Investigator's opinion.

Exclusion Criteria:

* Any other diagnosed forms of anemia, except for anemia of renal disease, including anemia in chronic diseases (C-reactive protein level \>20 mg/L at screening).
* Diagnosed lupus nephritis or chronic kidney disease due to systemic vasculitis.
* Platelet count \<100×109/L based on the results of screening examination.
* A high probability of early withdrawal from the study, in particular a planned (i.e., available information about a planned date and/or a suitable donor) kidney transplant surgery during the estimated period of participation in the study.
* A history of severe allergic reactions (anaphylactic shock or multiple drug allergy) according to the patient, and hypersensitivity to recombinant erythropoietins, polyethylene glycol or any components of the study drugs, or to iron (III) hydroxide sucrose complex.
* Vaccination less than 8 weeks before signing the ICF (according to the patient).
* Diagnosed liver cirrhosis.
* HIV infection.
* ALT, AST \>3хULN at screening.
* Decompensated heart disease (NYHA Class IV CHF).
* Resistant hypertension.
* Unstable angina.
* History of acute hemolysis episodes.
* Documented hemoglobinopathy, myelodysplastic syndrome, hematological malignancy, pure red cell aplasia.
* Severe secondary hyperparathyroidism (intact PTH\>1000 pg/mL at screening) or biopsy-confirmed bone marrow fibrosis (myelofibrosis).
* Documented episodes of gastrointestinal or other bleeding within less than 90 days prior to signing the ICF.
* Documented history of episodes of thrombosis (acute myocardial infarction, stroke, transient ischemic attacks, deep vein thrombosis, pulmonary thromboembolism within less than 6 months before the signing of the ICF, as well as long-term vascular access thrombosis within 30 days before the signing of the ICF.
* Seizure syndrome, including a history of or epilepsy during the screening period.
* Documented major surgery less than 30 days before signing the ICF.
* Documented blood transfusion within less than 90 days prior to signing the ICF.
* Any acute or chronic infections in the stage of exacerbation, as well as other chronic diseases that at the time of signing the informed consent, may adversely affect the patient's safety while using the study therapy in the opinion of the investigator.
* A history of severe depression, suicidal ideation, or attempted suicide.
* Documented malignancies other than cured basal-cell carcinoma and/or cervical carcinoma in situ with a remission duration of more than 5 years at the time of signing the ICF.
* Known alcohol or drug addiction, or current signs of alcohol/drug addiction, which, according to the investigator, is contraindication for the treatment with the test drug/reference drug or limits the treatment adherence.
* Participation in other clinical studies of medicinal products within less than 90 calendar days prior to signing the informed consent form for participation in this study.
* Pregnancy or breastfeeding.

Where this trial is running

Minsk and 1 other locations

• Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology — Minsk, Belarus (RECRUITING)
• B. Braun Avitum Russland Clinics Ltd. — Saint Petersburg, Russia (RECRUITING)

Conditions: Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D, CKD, Erythropoietin, Darbepoetin, Erythropoiesis-stimulating agent